#$%^&*AU2020101830A420200924.pdf#####ABSTRACT The invention discloses a Doxorubicin combined medicine, which comprises Doxorubicin, FEN Iprotein inhibitor and a pharmaceutically acceptable carrier. The invention also discloses the application of the combined medicines in preparing medicines for treating cancer, especially colon cancer. Experiments prove that the combination of Doxorubicin and FEN Iinhibitor SC13 can obviously enhance the therapeutic effect of Doxorubicin, obviously inhibit the proliferation of colon cancer cells and induce DNA damage and apoptosis after the combination. More importantly, combined use enhances the anti-tumor effect in mouse model, and reduces the dosage and toxic side effects of Doxorubicin. Therefore, Doxorubicin combined with FEN Iprotein inhibitor has a promising future in the prevention and treatment of colon cancer.
